Detail akcie CSL Ltd online

Business Summary: CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, CSL Ltd revenues increased 5% to $15.56B. Net income increased 14% to $3B. Revenues reflect CSL Behring segment increase of 27% to $11.16B, CSL Vifor segment increase of 9% to $2.23B, Rest of the world segment increase of 13% to $4.45B, China segment increase of 14% to $849M. Net income benefited from Research and development expenses decrease of 5% to $1.36B (expense).